

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

WRITER'S INTERNET ADDRESS:
TBOYCE@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:
512/536-3043

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

October 3, 2001

FILE: HACK:009US
10025109



CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

October 3, 2001

Date



The signature is handwritten in cursive ink, appearing to read "Thomas M. Boyce".

Thomas M. Boyce

Commissioner for Patents
Washington, DC 20231

RE: SN 09/065,082 "HYALURONIC ACID AS DNA CARRIER FOR GENE THERAPY AND VEGF ANTISENSE DNA TO TREAT ABNORMAL RETINAL VASCULARIZATION" - P.E. Rakoczy and I.J. Constable (Client Ref. VS:SJB:BK:FP5962)

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) Amendment: Substitute Specification Under 37 C.F.R. § 1.125(a) to Office Action dated September 6, 2001;
- (2) Substitute Specification; and
- (3) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct or credit said fees from or to Fulbright &

RECEIVED
OCT 12 2001
TECH CENTER 1600/2900

Commissioner for Patents
October 3, 2001
Page 2

Jaworski L.L.P. Account No.: 50-1212/10025109/TMB.

Respectfully submitted,



Thomas M. Boyce
Reg. No. 43,508

TB:SF
Encl.